OncoMatch/Clinical Trials/NCT06043323
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Is NCT06043323 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Axicabtagene Ciloleucel and Cyclophosphamide for follicular lymphoma.
Treatment: Axicabtagene Ciloleucel · Cyclophosphamide · Fludarabine phosphate · Prednisone · Diphenhydramine · Acetaminophen — To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
hemoglobin level ≥ 8 g/dl
Kidney function
crcl ≥ 45 ml/min/m2
Liver function
alt/ast ≤ 2.5 × uln or ≤ 5 x uln if documented liver involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify